
Benzinga Pro data, Aeglea BioTherapeutics (NASDAQ:AGLE) reported Q4 sales of $3.64 million. Earnings fell to a loss of $20.45 million, resulting in a 0.68% decrease from last quarter. Aeglea BioTherapeutics collected $1.40 million in revenue during Q3, but reported earnings showed a $20.31 million loss.